| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 10/17/2002 | CA2442092A1 Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication |
| 10/17/2002 | CA2441108A1 Process for making delivery matrix and uses thereof |
| 10/17/2002 | CA2439111A1 Mucosal boosting following parenteral priming |
| 10/16/2002 | EP1249247A2 Pharmaceutical preparation for the treatment of gynecological diseases |
| 10/16/2002 | EP1249241A1 Adsorbent for oral administration |
| 10/16/2002 | EP1249239A1 Antipruritic agents for external use |
| 10/16/2002 | EP1249238A2 Topical pharmaceutical composition comprising betanechol |
| 10/16/2002 | EP1249234A1 Method of preventing retinopathy of prematurity in a neonate |
| 10/16/2002 | EP1249232A1 Controlled release nanoparticles for percutaneous use and composition containing the same |
| 10/16/2002 | EP1249231A1 Pharmaceutical formulations comprising anti-inflammatory compounds and use thereof |
| 10/16/2002 | EP1249230A1 Microemulsion-preconcentrates and microemulsions comprising coenzyme Q10 |
| 10/16/2002 | EP1249229A2 Sustained delivery of an active agent using an implantable system |
| 10/16/2002 | EP1248858A1 Antisense modulation of caspase 8 expression |
| 10/16/2002 | EP1248830A1 Antimicrobial compositions |
| 10/16/2002 | EP1248791A1 Antisense modulation of caspase 3 expression |
| 10/16/2002 | EP1248774A2 Polyhydroxystilbenes and stilbene oxides as antipsoriatic agents and protein kinase inhibitors |
| 10/16/2002 | EP1248652A2 Stable aqueous deoxyfructosazine solution |
| 10/16/2002 | EP1248650A2 Improved dna vaccines for production-type animals |
| 10/16/2002 | EP1248636A1 Dextrin containing compositions for prevention of adhesions |
| 10/16/2002 | EP1248635A1 Antisense modulation of glycogen synthase kinase 3 alpha expression |
| 10/16/2002 | EP1248630A1 Composition, in particular cosmetic or dermatological composition, containing oligosaccharides and preparation method and cosmetic treatment method |
| 10/16/2002 | EP1248629A1 Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs |
| 10/16/2002 | EP1248625A2 Use of methylol-containing compounds for the manufacture of a medicament for the treatment of tumors |
| 10/16/2002 | EP1248619A1 Amorphous paroxetine compositon |
| 10/16/2002 | EP1248616A2 Functional coating of linezolid microcapsules for oral administration |
| 10/16/2002 | EP1248613A1 Clonidine preparations |
| 10/16/2002 | EP1248610A2 Use of at least a fatty ester for preparing a composition designed to inhibit 5-alpha-reductase activity, in pharmacology, in particular dermatology, in cosmetics and as food additive |
| 10/16/2002 | EP1248606A1 Use of fumaric acid derivatives for treating mitochondrial diseases |
| 10/16/2002 | EP1248603A2 Use of particular compounds for prophylaxis and treatment of hepatitis c |
| 10/16/2002 | EP1248600A1 Improved pharmaceutical formulations |
| 10/16/2002 | EP1248599A1 Multi-particulate form of medicament, comprising at least two differently coated forms of pellet |
| 10/16/2002 | EP1248598A1 Osmotic device having a preformed passageway that increases in size |
| 10/16/2002 | EP1248597A1 Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate |
| 10/16/2002 | EP1248596A2 Implantation kit comprising a support phase and a solvent |
| 10/16/2002 | EP1248595A1 Multi-step drug dosage forms |
| 10/16/2002 | EP1248594A1 Multi-spike release formulation for drug delivery |
| 10/16/2002 | EP1190123B1 Encapsulation of crystals via multilayer coatings |
| 10/16/2002 | EP1173521B1 Stable, aqueous dispersions and stable, water-dispersible dry powders of xanthophylls, and production and use of the same |
| 10/16/2002 | EP1098660B1 Encapsulation of water soluble peptides |
| 10/16/2002 | EP1085860B1 Formulations for the treatment of gastro-oesophageal reflux |
| 10/16/2002 | EP1083884B1 Process for the stabilisation of polyvinylpyrrolidone formulations |
| 10/16/2002 | EP1037652B1 Pharmaceutical compositions based on dalfopristin and quinupristin and preparation |
| 10/16/2002 | EP1019417B1 Phospholipid analogue compounds |
| 10/16/2002 | EP0998279B1 Pharmaceutical injection solution containing taxol |
| 10/16/2002 | EP0915658B1 Film-building agent useful to protect against infections |
| 10/16/2002 | EP0881953B1 Electrostatic coating of small falling objects |
| 10/16/2002 | EP0877605B1 Solid instant-release forms of administration and process for producing the same |
| 10/16/2002 | EP0844881B1 Laxative comprising lactitol and psyllium |
| 10/16/2002 | EP0831826B1 Pharmaceutical composition comprising a proteinase inhibitor and a monoglyceride |
| 10/16/2002 | EP0802731B1 Prophylactic treatment of allergic contact dermatitis |
| 10/16/2002 | EP0789559B2 Pharmaceutical composition containing a fusible carrier and method for producing the same |
| 10/16/2002 | EP0759303B1 Colon-specific drug release system |
| 10/16/2002 | EP0749277B1 Coprocessed galactomannan - glucomannan |
| 10/16/2002 | EP0721343B1 Pharmaceutical formulations of nerve growth factor |
| 10/16/2002 | EP0637976B2 Medicament for disinfection of the oral cavity |
| 10/16/2002 | EP0619742B1 Transfection of lung via aerosolized transgene delivery |
| 10/16/2002 | EP0528978B1 Mikrocaspules for controlled release and their use to stimulate nerve fiber growth |
| 10/16/2002 | CN2516174Y Venereal diseases prevention and treatment pad |
| 10/16/2002 | CN2516159Y Fumigation incense with compound medicine layer |
| 10/16/2002 | CN1374874A Use of fatty acid/amino acid soaps to enhance antimicrobial effectiveness of topical pharmaceutical compositions |
| 10/16/2002 | CN1374873A Anionic amino acid based surfactants to enhance antimicrobial effectiveness of topical pharmaceutical compositions |
| 10/16/2002 | CN1374867A Quetiapine granules |
| 10/16/2002 | CN1374866A Polymorphs of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-alpha]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto |
| 10/16/2002 | CN1374862A Directly compressible, ultra fine acetaminophen compositions and process for producing same |
| 10/16/2002 | CN1374861A Methods for modulating the human sexual response |
| 10/16/2002 | CN1374860A Utilization of a highly fluorinated oligomeric alkan in ophthalmology |
| 10/16/2002 | CN1374859A 药物粉剂 Drug powder |
| 10/16/2002 | CN1374857A Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins |
| 10/16/2002 | CN1374838A Method for stabilizing liquid nutritional products and products so stabilized |
| 10/16/2002 | CN1374835A Method for the production of polyvinylpyrrolidone-iodine in an aqueous solution |
| 10/16/2002 | CN1374139A Brain invigorating belt |
| 10/16/2002 | CN1374132A Prepn of core-shell type nano compound hydroxyapatiti-liposome particle |
| 10/16/2002 | CN1374123A Ningtongling as a pain killer |
| 10/16/2002 | CN1374116A Indusrialized anjd standardized Chinese medicine decoction supplying scheme |
| 10/16/2002 | CN1374114A New prepn process of Lideri as one traditional Mongoliam medicine |
| 10/16/2002 | CN1374112A New prepn process of Zhuanglong as one traditional Mongolian medicine |
| 10/16/2002 | CN1374111A New prepn process of Manu as one traditional Mongolian medicine |
| 10/16/2002 | CN1374106A Chinese medicine prepn for treating hepatitis B and its prepn process |
| 10/16/2002 | CN1374102A Dermatitis treating ointment and its prepn |
| 10/16/2002 | CN1374085A Externally used and ophthalmic gel prepn of levo ofloxacin |
| 10/16/2002 | CN1374031A Daharian rose fruit extractive capsule |
| 10/16/2002 | CN1092515C Powdery aerosol |
| 10/15/2002 | US6466944 Method for creation, management, and use of files containing multiple virtual data streams using standard file system APIs |
| 10/15/2002 | US6465709 Exothermic bandage |
| 10/15/2002 | US6465626 Pharmaceutical compositions of chitosan with type-A gelatin |
| 10/15/2002 | US6465506 Instillation techniques for ophthalmic agents to enhance treatment effect |
| 10/15/2002 | US6465502 Additional therapeutic use |
| 10/15/2002 | US6465469 Depression, migraine headaches, panic disorders, post traumatic stress disorder and sleep disorders; side effect reduction |
| 10/15/2002 | US6465447 Solvent extraction, concentration and chromatographic purification of active fraction of fruit body of tochukaso; 3,5,6-trihydroxy-10,13,14-trimethyl-11-acetoxy-17-(2-(5,6-dimethyl-hept-3 -ene))gonane-3-one |
| 10/15/2002 | US6465440 Antimutagenic compositions for treatment and prevention of photodamage to skin |
| 10/15/2002 | US6465439 Pharmaceutical compositions |
| 10/15/2002 | US6465426 Acylation |
| 10/15/2002 | US6465425 Biodegradable materials, such as polymers, encapsulating protein medicaments (such as beta-ifn) can be employed as a sustained delivery system |
| 10/15/2002 | US6465226 Passing drops into precipitation bath containing calcium compound; encapsulation, crosslinking, gelation; separation from nozzle electrostatically |
| 10/15/2002 | US6465188 Nucleic acid ligand complexes |
| 10/15/2002 | US6465017 Granulation of the powder with an aqueous solution, drying, compression into tablets or capsules |
| 10/15/2002 | US6465016 Cyclosporiine particles |
| 10/15/2002 | US6465014 20 to 40% sodium alginate, 4 to 12% propylene glycol alginate (pga), 40 to 80% of a pharmaceutical; diffusion barrier formed by the interaction of a ph-dependent gelling material and a ph-independent non-gelling material |
| 10/15/2002 | US6465013 Folic acid in solid dosage forms |
| 10/15/2002 | US6465012 Tablet form with more than 76% by weight of gabapentin; made by spray coating with binder solution and compressing into non-friable tablets; improved compressibility, compactibility |